EyeCRO scientists contribute to paper published in Biology

Inmed Pharmaceuticals Inc. (NASD: INM) has secured a worldwide license to formulate any cannabinoid molecule using MiDROPS® for ophthalmic instillation. Click here to read the full press release.

“Researchers have discovered a technique for directly reprogramming skin cells into light-sensing rod photoreceptors used for vision. The lab-made rods enabled blind mice to detect light after the cells were transplanted into the animals’ eyes. The work, funded by the National Eye Institute (NEI), published April 15 in Nature.” (Click here to read rest of article)

Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model. Click here to read more

EyeCRO recently requested and conducted a pre-IND meeting with the US FDA to discuss the nonclinical and clinical development plans for CsA-MiDROPS™ to treat Dry Eye Disease. The agency was supportive of the project and agreed that the proposed nonclinical and CMC studies would allow entry into a phase II clinical trial. Also discussed was…

EyeCRO LLC has been awarded full accreditation from AAALAC International for their facility in Oklahoma City, OK. EyeCRO joins the Department of Veterans Affairs, the Oklahoma Medical Research Foundation, Oklahoma State University, and the University of Oklahoma Health Sciences Center as the fifth institution in Oklahoma to receive this prestigious endorsement. The award letter from…

EyeCRO scientist Jarrod Harman contributed to a paper focused on X-linked juvenile retinoschisis published in Experimental Eye Research. This paper expands the mechanistic understanding of XLRS. Read the full paper here https://www.sciencedirect.com/science/article/pii/S0014483523002129?dgcid=coauthor